Ovarian biphasic or triphasic teratoma

Summary

Ovarian biphasic or triphasic teratoma (MONDO:0003821) is a disease. A subtype of ovarian teratoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ovarian biphasic or triphasic teratoma
Mondo ID	MONDO:0003821
DOID	DOID:6232
NCIT	C39992
UMLS	C1518691
MedGen	274086
GARD	0023684
Is cancer (heuristic)	no

Also known as: ovarian biphasic or triphasic teratoma

Disease family

This is a subtype of ovarian teratoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › germ cell tumor › nongerminomatous germ cell tumor › teratoma › gonadal teratoma › ovarian teratoma › ovarian biphasic or triphasic teratoma

Related subtypes (2): ovarian monodermal teratoma, childhood teratoma of the ovary

Subtypes (2): mature ovarian teratoma, immature ovarian teratoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.